MedTrace Logo

A Clinical Trial of XZP-3287 for Material Balance

NCT05478109 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-07-28

No results posted yet for this study

Summary

A single-centre, open-label, mass balance and biotransformation study in healthy male subjects utilising a single oral dose of \[14C\] XZP-3287

Conditions

  • Healthy Male Subjects

Interventions

DRUG

[14C]XZP-3287

360 mg suspension containing 50µCi of \[14C\] XZP-3287

Sponsors & Collaborators

  • Xuanzhu Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-02
Primary Completion
2023-01-04
Completion
2023-01-04

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05478109 on ClinicalTrials.gov